Saturday 17 October 2026 Export PBH’s income statement to Excel — free account

Prestige Consumer Healthcare Inc.

PBH Healthcare Drug Manufacturers Specialty & Generic

Prestige Consumer Healthcare Inc.’s revenue for fiscal 2026 (year ended March 2026) was $1.1 billion, down 4.31% from fiscal 2025. In the quarter to June 2026, revenue grew 6.48%, EPS fell 36.5%, free cash flow fell 14.2% and total debt rose 100.9%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

49.92 0.72 +1.46%

Follow PBH

Alert me

Market cap: $2.3B
P/E: 13.9×
Fwd P/E: 10.3×
Dividend yield: —
F-score: 5/9
Altman Z: 2.48
Beneish M: −2.53
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 0.42

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	2	—	—	1	—	—	4	—	—	—	—	—

Insider Ownership 1.65%

Capital & Financial Ratios $m

Market Cap 2,330.00

Revenue 1,104.89

Net Income 172.01

Free Cash Flow 235.36

Net Debt 1,945.83

Current Ratio 3.23

Debt/Equity 1.06

P/E ratio 13.91

Fwd P/E 10.30

P/S ratio 2.14

P/B ratio 1.24

Past 5Y EPS Growth 3.77%

This Y EPS Growth 4.66%

Next Y EPS Growth 11.97%

Next Y revenue growth 17.02%

Next 5Y EPS Growth 6.86%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/E against its own 10 years 30.12%

10-year low 10-year high

P/S against its own 10 years 28.46%

10-year low 10-year high

P/B against its own 10 years 4.35%

10-year low 10-year high

EV/Sales against its own 10 years 48.69%

10-year low 10-year high

EV/FCF against its own 10 years 36.16%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2026	Powerpack
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2018	0.48	0.48

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2024	2025	2026	Q'26
Cash	46	98	64	89
Receivables	177	194	192	187
Inventory	139	148	159	190
Other	—	—	—	—
	375	448	431	497

	2024	2025	2026	Q'26
Payables	39	19	23	37
ST’ Debt	—	—	—	10
Other	—	—	—	—
	117	107	121	154

Compound Annual Growth %

	10y	5y	3y
Sales	3.05%	2.91%	(1.17%)
Cash Flow	3.87%	1.80%	3.90%
Earnings	6.66%	2.93%	0.00%
Book Value	9.75%	6.80%	9.26%

Revenue $m

	Jun	Sep	Dec	Mar	Year
’26	266	—	—	—	—
’26	250	274	283	282	1,089
’25	267	284	290	297	1,138
’24	279	286	283	277	1,125
’23	277	289	276	286	1,128
’22	269	276	274	267	1,087
’21	229	237	239	238	943

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Jun	Sep	Dec	Mar	Year
’26	71	—	—	—	—
’26	79	57	78	43	258
’25	55	70	65	62	252
’24	48	62	71	67	249
’23	58	58	55	59	230
’22	69	61	66	63	260
’21	75	52	49	59	236

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Jun	Sep	Dec	Mar	Year
’26	67	—	—	—	—
’26	78	55	75	38	246
’25	54	68	64	58	243
’24	47	60	69	64	239
’23	57	55	53	56	222
’22	68	58	64	60	250
’21	73	43	43	54	213

Fiscal quarters ending in the months shown.

EPS $

	Jun	Sep	Dec	Mar	Year
’26	0.61	—	—	—	—
’26	0.95	0.86	0.97	1.13	3.91
’25	0.98	1.09	1.22	1.00	4.29
’24	1.06	1.07	1.06	0.98	4.17
’23	1.09	1.02	1.04	(4.83)	(1.65)
’22	1.14	0.89	0.99	1.02	4.04
’21	0.86	0.88	0.81	0.70	3.25

Fiscal quarters ending in the months shown.

Group	Line	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027e
Price, $
Price, $	Low	40.11	27.84	26.25	27.40	34.74	48.51	52.90	57.95	57.25	42.62	Analyst estimates 2027–2029 Powerpack
	High	59.63	46.44	41.38	46.12	63.83	64.05	68.54	86.36	90.04	71.07
People
People	Employees	530	530	520	520	505	535	560	570	600	890
	Revenue/emp, $m	1.66	1.96	1.88	1.85	1.87	2.03	2.01	1.97	1.90	1.22
Income, $m
Income, $m	Revenue	882	1,041	976	963	943	1,087	1,128	1,125	1,138	1,089
	Gross margin, %	56.72	55.37	56.94	57.34	58.03	57.11	55.45	55.49	55.76	54.71
	EBT	111	107	(38)	191	204	262	(94)	276	284	257
	EBT margin, %	12.57	10.29	(3.90)	19.85	21.64	24.15	(8.33)	24.53	24.98	23.65
	Net income	69	340	(36)	142	165	205	(82)	209	215	190
	Depreciation	34	40	38	33	35	36	37	36	32	33
Per share, $
Per share, $	Revenue	16.65	19.61	18.74	18.99	18.79	21.62	22.60	22.62	22.89	22.47
	Earnings	1.31	6.40	(0.69)	2.81	3.28	4.09	(1.65)	4.21	4.32	3.93
	Cash flow	2.81	3.96	3.64	4.28	4.69	5.17	4.60	5.00	5.06	5.32
	Capex	(0.05)	(0.24)	(0.20)	(0.29)	(0.44)	(0.19)	(0.16)	(0.19)	(0.17)	(0.23)
	Free cash flow	2.75	3.72	3.43	3.99	4.25	4.98	4.45	4.81	4.90	5.09
	Book value	15.53	22.20	21.05	23.09	27.05	31.39	29.01	33.26	36.92	38.95
	Shares, m	53	53	52	51	50	50	50	50	50	48
Valuation, ×
Valuation, ×	P/E	42.09	5.16	0.00	13.01	13.44	12.98	0.00	17.03	19.90	15.04
	P/S	3.34	1.68	1.57	1.93	2.35	2.45	2.77	3.17	3.76	2.64
	P/B	3.58	1.49	1.39	1.59	1.63	1.69	2.16	2.15	2.33	1.52
	EV/Sales	5.79	3.57	3.39	3.64	3.90	3.79	3.92	4.14	4.57	3.52
	EV/FCF	35.01	18.83	18.50	17.32	17.23	16.48	19.93	19.45	21.36	15.54
Cash, $m
Cash, $m	Operating cash flow	149	210	189	217	236	260	230	249	252	258
	Capex	(3)	(13)	(10)	(15)	(22)	(10)	(8)	(10)	(8)	(11)
	Free cash flow	146	198	179	203	213	250	222	239	243	246
Balance, $m
Balance, $m	Working capital	172	180	174	216	148	150	231	258	342	311
	Total debt	2,194	1,993	1,799	1,735	1,486	1,481	1,347	1,126	1,013	1,012
	Net debt	2,152	1,960	1,771	1,640	1,454	1,454	1,289	1,080	915	948
	Shareholders’ equity	823	1,179	1,096	1,171	1,358	1,578	1,447	1,655	1,835	1,888
Returns, %
Returns, %	ROA	2.02	8.85	(0.99)	4.09	4.74	5.79	(2.34)	6.28	6.39	5.52
	ROIC	4.32	4.29	1.47	6.47	6.61	6.80	(0.51)	7.83	7.65	6.82
	ROE	8.86	33.94	(3.15)	12.55	13.02	13.99	(5.44)	13.50	12.30	10.22

Negative figures in brackets.

All 10 years →

Fiscal years to Mar 2026 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
LQDA Liquidia Corporation	$3.1B	21.9×	18.5×	+1,842.73% (above 0%: growing)	n/m	+270.23% (above 0%: growing)	93.27%	49.81%	Compare
HCM HUTCHMED (China) Limited Sponsored ADR	$2.4B	— (loss-making)	—	+510.07% (above 0%: growing)	+419.25% (above 0%: growing)	+113.21% (above 0%: growing)	60.90%	0.00%	Compare
PBH Prestige Consumer Healthcare Inc.	$2.3B	13.9×	10.3×	+6.48% (above 0%: growing)	−36.46% (below 0%: shrinking)	−14.19% (below 0%: shrinking)	51.25%	19.77%
SUPN Supernus Pharmaceuticals, Inc.	$2.3B	— (loss-making)	103×	+32.40% (above 0%: growing)	n/m	−109.26% (below 0%: shrinking)	84.63%	(26.46%)	Compare
PRGO Perrigo Company plc	$2.3B	— (loss-making)	— (loss-making)	−3.17% (below 0%: shrinking)	n/m	+18.37% (above 0%: growing)	30.69%	2.31%	Compare
ALVO Alvotech	$2.1B	— (loss-making)	8.9×	+2,310.95% (above 0%: growing)	−99.51% (below 0%: shrinking)	−496.58% (below 0%: shrinking)	56.47%	9.14%	Compare
BCRX BioCryst Pharmaceuticals, Inc.	$2.1B	— (loss-making)	— (loss-making)	+33.61% (above 0%: growing)	+1,450.00% (above 0%: growing)	+153.22% (above 0%: growing)	98.24%	45.12%	Compare
XERS Xeris Biopharma Holdings, Inc.	$1.8B	— (loss-making)	54.5×	+28.74% (above 0%: growing)	n/m	+8,403.09% (above 0%: growing)	86.41%	5.62%	Compare
ANIP ANI Pharmaceuticals, Inc.	$1.7B	14.9×	14.5×	+25.87% (above 0%: growing)	+194.59% (above 0%: growing)	−22.19% (below 0%: shrinking)	62.35%	15.21%	Compare
Median of peers	$2.2B	—	18.5×	+33.01%	+306.92%	+65.79%	73.49%	7.38%

All 86 Drug Manufacturers Specialty & Generic stocks →

Prestige Consumer Healthcare Inc. (PBH) key facts

Concern: Prestige Consumer Healthcare Inc.’s revenue for fiscal 2026 (year ended March 2026) was $1.1 billion, down 4.31% from fiscal 2025.
Concern: Net income was $190.3 million, or $3.93 per share (basic), a net margin of 17.5%.
Prestige Consumer Healthcare Inc. (PBH) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector, listed on the New York Stock Exchange.
As of October 16, 2026, PBH traded at $49.92, a market capitalization of $2.3 billion.
At that price the stock trades at 13.9× trailing-twelve-month earnings and 2.1× sales; its P/E is higher than 30% of its own readings over the past ten years.
Return on equity was 10.2% and debt-to-equity 1.06.
Its Piotroski F-score is 5 out of 9 and its Altman Z-score is 2.48 (grey zone) for fiscal 2026.